Pursuits
‘Love Hormone’ Promises Safer Births After Pfizer Flop
This article is for subscribers only.
A hormone treatment based on technology used in Pfizer Inc.’s failed inhalable insulin shows promise in fighting the leading cause of maternal mortality.
Six years after Pfizer pulled Exubera from the market at a cost of more than $2.8 billion, scientists at Melbourne’s Monash University are revisiting the inhalable technology to deliver a life-saving medicine to stop post-delivery hemorrhage.